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-23.78 vs. -19.71 in WHO-DAS-II (F24.5, p0.001), respectively. After discounting
the effect on anxiety reduction over time, the estimated PGB effect over UC in-
crease on both sleep disturbances and disability scores were still significant (g-
3.99, p0.001 and g-3.07, p0.001, respectively). Mediation analysis showed that
70% and 58% of the direct effect of PGB over, respectively, sleep disturbances and
disability remained after discounting the mediated effect of anxiety improvement.
CONCLUSIONS: Adding pregabalin to usual care produced better improvements in
sleep disturbances and disability related GAD symptoms in outpatients treated in
real world conditions. 70% and 58% of the total effect of PGB over usual care was
explained by its direct effect not mediated by improvements in anxiety symptoms.
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OBJECTIVES: Specific instruments are developed measuring HRQoL in children and
adolescents. Currently, these instruments are not applicable in health economic
studies as valuations for health states are lacking. The aim of the current study was
to compare the psychometric properties of a generic child-specific and a generic
preference based instrument in children and adolescents with ADHD. METHODS:
A questionnaire survey was performed among parents with a child diagnosed with
ADHD. Results on the proxy versions of the KIDSCREEN-10 and the EQ-5D were
used to compare the constructs describing HRQoL of the instruments and their
responsiveness to different health states. Principal Component Analaysis (PCA)
with varimax rotation was used for identifying factors underlying the constructs of
both instruments. A comparison was performed of the index scores on both instru-
ments between respondents with different stimulant medication profiles and dif-
ferent comorbidity profiles using Student’s t-tests. Additionally, Cohen’s effect
sizes were calculated for an indirect comparison of the instruments’ responsive-
ness and discriminating ability. RESULTS: Using the EQ-5D dimensions and the
items of the KIDSCREEN -10 the PCA identified 5 separate components of HRQoL. A
physical component and a mental component included a combination of EQ-5D
dimensions and KIDSCREEN-10 items. No associations of the EQ-5D dimensions
‘self-care’ and ‘usual activities’ and KIDSCREEN-10 items was found. Additionally,
no association was found of KIDSCREEN-10 items related to performance at school
and satisfaction with free time activities and EQ-5D dimensions. Scores of both
instruments differed significantly according to respondents’ treatment and comor-
bidity profile. Cohen’s effect sizes indicated comparable responsiveness and dis-
criminative ability of the instruments. CONCLUSIONS: The results highlight that
the two instruments measure different constructs of HRQoL. Despite this, the anal-
yses showed comparable responsiveness to different health states and discrimi-
native ability of the instruments. These results suggest that the KIDSCREEN and
the EQ-5D are complementary instruments.
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OBJECTIVES: Patient-reported outcomes (PROs) are widely used in mental health
research to assess treatment benefits for patients. The objective of this study is to
evaluate literature describing health-related quality of life (HR-QoL) PRO tools used
in schizophrenia, and to report level of validation of available instruments.
METHODS: A systematic search of the EMBASE, Pubmed and ISPOR conference
abstracts databases was conducted. No restrictions on date of submission or geo-
graphical region were applied. Conceptual framework, reliability (internal consis-
tency and reproducibility), validity (content validity and construct validity) and
sensitivity to change for the measures were evaluated. RESULTS: Fifiteen instru-
ments were identified (4 generic, 3 severe mental illness specific, 5 schizophrenia
specific and for 2 instruments it was not possible to retrieve this information).
Among generic questionnaires EQ-5D had the highest level of validity and a rea-
sonable level of sensitivity to change. Among severe mental illness specific ques-
tionnaires, The Tolerability And Quality Of Life Questionnaire (TOOL) showed high
validity, reliability and sensitivity. Subjective experience of antipsychotic drugs
was well-assessed with the Subjective Well-being under Neuroleptics Scale (SWN).
The validity of the SWN was acceptable and the tool included assessment of sub-
jective experience to evaluate differential effects of anti-psychotics and dose reg-
imens. Amongst the schizophrenia specific PROs to evaluate QoL, the quality Of
Life Questionnaire In Schizophrenia (S-QoL) was judged to have a high level of
validity and sensitivity to change and the quality of life measure for persons with
schizophrenia (QOLM-S), a 30-item scale, also showed internal reliability and con-
struct validity. CONCLUSIONS: Within schizophrenia, EQ-5D appears to have high
level of validity and sensitivity to change compared to other generic instruments.
Two disease specific instruments were considered as validated among which S-
QoL was the only one to show sensitivity to change. Our recommendation would be
to use EQ-5D or S-QoL in future studies.
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OBJECTIVES: To evaluate health-related quality of life (HRQOL) and its determi-
nants in Japanese patients with chronic schizophrenia on antipsychotic
polypharmacy. METHODS: The data were collected from an ongoing prospective
randomized comparative study entitled, “The clinical study to correct multiple and
large amount of administering to antipsychotic safely and effectively,” conducted
in Japan. The subjects were 133 Japanese patients diagnosed with schizophrenia.
Of these, 75 were evaluated once, while 49 and 9 were evaluated twice and three
times, respectively. Therefore, we were able to use data from a total of 200 evalu-
ations. The subjects’ mental status was assessed with the Manchester Scale (MS).
The severity of extrapyramidal side effects was assessed with the Drug-Induced
Extrapyramidal Symptoms Scale (DIEPSS), and the severity of autonomic side ef-
fects was assessed with the subscales extracted from the “Udvalg for Kliniske
Undersogelser(UKU).” HRQOL was evaluated using the EuroQOL (the EQ-5D and the
visual analogue scale, EQ-VAS). Independent determinants of HRQOL were identi-
fied using stepwise multiple regression analysis. RESULTS: The mean age (stan-
dard deviation) of the subjects was 56.4 (11.4). There were 54 females and 78 males.
The average disease duration was 29.2 (12.3) years. The mean utility score derived
from the EQ-5D of the total of 200 evaluations was 0.711 (0.211). The mean EQ-VAS
score was 0.632 (0.213). Independent determinants of reduced utility score were:
severity of “hallucinations” in the MS; “diarrhea” and “orthostatic dizziness” in the
UKU; severity of “gait” in the DIEPSS; and female gender.CONCLUSIONS:This is the
first report investigating the determinants of HRQOL in patients with schizophre-
nia in Japan. This report suggests that in addition to hallucinations, several side
effects induced by antipsychotics, such as diarrhea, postural hypotension, and
Parkinsonism, might play an important role in patients with schizophrenia.
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OBJECTIVES: To elicit the willingness to pay (WTP) of different stakeholders re-
garding different aspects of treatment of schizophrenia.METHODS:We conducted
a survey of 259 Swedes with a serious mental disorder, 263 relatives of individuals
suffering from a serious mental disorder and 528 people sampled from the general
population. We designed a discrete choice experiment (DCE) to determine respon-
dents’ WTP. Conditional logit was used to derive the WTP results. RESULTS: The
value of reducing the required frequency from every other week to once a month is
141 SEK per month for patients, 192 SEK per month for relatives, and 227 SEK per
month for the general population. The value of reducing the required frequency
from every other week to once every 3 months is 269 SEK per month for patients, 349
SEK per month for relatives, and 414 SEK per month for the general population.
Accompanying visits every 3 months with a consultation about general well-being
is worth 149 SEK per month for patients, 247 SEK per month for relatives, and 148
SEK per month for the general population. The value of being able to store medi-
cation outside a refrigerator at room temperature instead of in a refrigerator is 130
SEK per month for patients, 176 SEK per month for relatives, and 198 SEK per month
for the general population. CONCLUSIONS: There is a significant, positive willing-
ness to pay for reduced injection frequency (at doctors’ or cliniques), not having to
store drugs in refrigerator compared to storage at room temperature, and having
consultation about general well-being every three months.
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OBJECTIVES: Stigma and prejudice surrounding people with mental illnesses are a
major impediment that contributes to prevent them to access to health care. This
is the first part of a project that aims to assess impact of mental disorders stigma on
willingness to pay for health care. The first part of the project describes public
beliefs and attitudes about schizophrenia, major depression and psychotropic
drugs. METHODS: Three questionnaires were administered online to a represen-
tative sample of 2400 French people. 800 persons answered a questionnaire on
schizophrenia, 800 on major depression and 800 about psychotropic drugs. They
were asked to address a validated questionnaire. RESULTS:All 2400 questionnaires
were fully completed. 57.9% (resp. 35.3%) of people reported being not comfortable
in presence of a schizophrenic patient (resp. major depression), while 18.6% (resp.
39.0%) reported they did. More than 72.1% (resp. 80.9%) felt the need to help people
suffering from schizophrenia (resp. major depression), although 60.0% (resp. 16.3%)
think that such patients are strange, and 36.1% (resp. 14.5%) think they are danger-
ous. 9.1% agree with the fact that psychotropic treatment helps people to better
support the concerns of everyday life and 8.8% agree with taking these medicines
if the person suffers constantly of light mood swings. CONCLUSIONS: This study
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suggests that stigmatization around schizophrenia and major depression is pres-
ent in France; the public willing to help mental disease patients as demonstrated by
our study, stress on the relevance of investing in mental health to reduce the
enormous associated costs that burden individuals, families and societies. This
stigmatization contributes to marginalize patients, exclude them from health care
management and affects their disease severity. Impact of stigma on willingness to
pay is being assessed.
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OBJECTIVES: Health care systems face increased prevalence and costs of mental
illness. The objective of this study is to provide a comprehensive overview of per-
sonalized medicine for major psychiatric disorders with focus on developing mo-
lecular imaging biomarker.METHODS:A systematic review was conducted to iden-
tify current molecular imaging methods in psychiatric disorders. The following
databases were searched between 2009 to February 2012: Medline, PubMed, Sco-
pus, Cochrane Library, PsycINFO, Psychiatry Online Journals, PSYINDEX as well as
individual journals. The extraction of data consisted of the biomarker, tracer and
the targeted disease. According to Fryback and Thornbury, the level of diagnostic
efficiency was defined as selection criterion for the technology. The most promis-
ing biomarker was then examined by indication, treatment phase and stage of
development. An update search for the identified technology was the performed
following the PRISMA guidelines. RESULTS: Several emerging molecular imaging
technologies were identified, but most imaging technologies still have to prove
technical efficiency. The most mentioned radiotracers are Pittsburgh Compound B
for amyloid imaging (45 articles) in Alzheimer’s disease, Raclopride for dopamine 2
imaging (25 articles) and DASB for Serotonin 1A imaging (17 articles). Within this,
amyloid imaging is the most advanced technology. Thirty-one studies examined
patients with and without diagnosis of Alzheimer’s disease. Amyloid imaging pro-
vides a high reliability in diagnosis, but cognitive measures only showed weak
correlations. CONCLUSIONS: The current status of molecular imaging in psychia-
try was assessed. The most promising technology, amyloid imaging in Alzheimer’s
disease, is expected to improve the diagnosis, therapy, as well as the organisation
of care. Preclinical diagnosis can be a base for further treatment options like anti-
amyloid therapy. “Personalized medicine” like molecular imaging offers an effec-
tive solution for an accurate screening, diagnosis and treatment.
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OBJECTIVES: Bipolar disorder (BD) is a psychiatric disease characterized by recur-
ring mood episodes. One pharmacological treatment for BD is quetiapine fumarate,
which exists in two formulations; extended release (XR) and immediate release
(IR). The aim was to describe patient characteristics and treatment patterns for BD
patients treated with quetiapine IR continuously vs. patients who were switched to
XR. METHODS: BD patients with hospital admittance and prescription of quetiap-
ine were identified from the Swedish National Patient Register and linked to the
Prescribed Drug Register (ctw.gov, NCT01455961). Index date was defined as first
prescription of quetiapine XR or first prescription of IR after 1st January 2009. End of
observation was 31st December 2011. Data were analyzed by descriptive methods.
RESULTS:A total of 5219 BD patients with prescriptions of XR/IR were identified. Of
the 1761 patients using IR; 1303 patients later switched to XR, whereas 458 patients
continuously used IR during the study period. Patients who later switched from IR
to XR had more single depressions (47.1 vs. 40.4%) and anxiety disorders (36.1 vs.
30.3%), lower mean quetiapine IR dose (218 vs. 270 mg), and less medications for
somatic diseases (39.0 vs. 46.5%), compared to patients continuing on IR. Following
switch to XR, the number of concomitant medications (atypical antipsychotics and
antidepressants) was reduced by 5.9 and 6.0%; while it increased by 3.0 and 0.7% in
the IR continuous group, respectively. The quetiapine dose post-switch was higher
in the group that switched to XR vs. the IR continuous group, 305 vs. 252 mg.
CONCLUSIONS: Patients with bipolar disorder who switched to quetiapine XR had
more psychiatric co-morbidity before switch compared to continuous IR patients.
Following switch to XR, a higher mean quetiapine dose compared to the continu-
ous IR group, and a decreased use of concomitant medications was found in this
patient group.
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OBJECTIVES: To analyze the add-on and switch patterns for patients who dis-
pensed different formulation of methylphenidate, in the South-West region of
Sweden. METHODS: This was a retrospective database study of medication utili-
zation amongst patients from the South-West region of Sweden (1.5 million inhab-
itants). All patients who dispensed Methylphenidate (ATC code: N06BA04), from
2006 to 2010 were included in the study. A dispatch was classified as new, switch,
add-on, or continuation. All dispatches were annotated, at the drug type level, as
either new (no other methylphenidate products within 90 days), add-on (another
methylphenidate products dispatched both before and after), switch (another
methylphenidate products dispatched before, but not after), or continuation (dis-
patched same drug type within 90 days). RESULTS: A total of 11731 patients had at
least one methylphenidate filled prescription. The total number of dispatches for
these patients were 219 750. 77% of all patients had been dispatched long acting
methylphenidate, 44% modified release methylphenidate and 30% short acting
methylphenidate. Long acting methylphenidate was dispatched as a new prescrip-
tion in 19% of all dispatches, in 0.5% as add-on, 0.9% as switch, and in 80% as
continuation. For modified release methylphenidate the distribution was 15%
(new), 1% (add-on), 3% (switch), and 81% (continuation). For short acting methyl-
phenidate the distribution was 10%, 10%, 8%, and 72%. CONCLUSIONS: Long acting
methylphenidate is the most dispatched product type. Both long acting and mod-
ified release methylphenidate had first line treatment profiles, of which it was most
pronounced for long acting methylphenidate (1% add-on or switch). Short acting
methylphenidate is used more as an add-on or switch therapy with 10% as add-on,
8% as switch, and only 10% as new dispatches.
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OBJECTIVES: The primary objective was to compare medical resource use and cost
amongst patients diagnosed with anorexia nervosa (AN), bulimia nervosa (BN), and
binge eating disorder (BED). METHODS: Eating disorders were identified retrospec-
tively using IMS LifeLink claims data from January 2006 through June 2010. Eating
disorder not otherwise specified (EDNOS) patients were subdivided into two
groups: obese and non-obese. BED does not currently have a DSM-IV diagnosis, so
obese subjects coded with EDNOS were used as a proxy for BED patients. Comor-
bidities, treatments, health care utilization, and costs were collected for 12 months
before and after an eating disorder diagnosis. To compare outcomes in the fol-
low-up period, Propensity Score Matching (PSM) was used to match each eating
disorder cohort to a comparable control group based on pre-index demographic
and clinical characteristics. RESULTS: Obese EDNOS patients had higher health
care resource utilization than all other eating disorder groups. The biggest differ-
ence came from non-psychiatric related inpatient visits. Obese EDNOS patients
(N4,534) had a total cost of $19,063 compared to $9,362 for the reference group
(p-value0.001); non-obese EDNOS patients (N4,401) total cost was $10,022 vs.
$5,444 for the controls (p-value0.001). AN patients (N1,942) had an average total
cost of $14,961 versus $6,828 for the control patients (p-value0.001) while BN
patients (N2,334) had an average total cost of $9,980 versus $5,840 for the controls
(p-value0.001).CONCLUSIONS:Compared to matched control groups, health care
costs were significantly greater for each eating disorder group. More frequent in-
patient, outpatient, and outpatient ER visits characterized all three treatment
groups. Overall, BED patients appear to have had the highest average annual cost of
all cohorts.
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OBJECTIVES: With population aging across European countries, Alzheimer’s dis-
ease (AD) represents an increasing burden for societies and health care payers. The
present study assessed the health-economic potential benefits of hypothetical in-
terventions in preventing AD across 9 European countries. METHODS: A 3-state
dynamic Markov model was developed in a population of 65 year old patients.
Age-specific conversion rates from No AD to AD were retrieved from a European
study. On top of the non-specific mortality rates, an adjustment factor was applied
to patients with AD. Annual costs data for AD were retrieved for 9 major European
countries including France, Germany and the UK. These costs (societal perspective)
ranged from €9,856 in Ireland to €36,885 in the UK. Two preventing AD interven-
tions were simulated, based on relative risk reductions (RRR) of 0.8 and 0.5.
RESULTS: In order to be break-even, annual costs of interventions ranged from €90
in Denmark, Ireland and Sweden to €335 in the UK and from €230 up to €831 in the
same countries, respectively for interventions with RRR 0.8 and 0.5. For a given
willingness to pay of €50,000, interventions were cost-effective in France at €380
and €970, in Germany at €290 and €770, respectively for RRR of 0.8 and 0.5. For these
2 interventions, average per patients expected savings ranged from €1,859 and
€4,829, respectively for RRR 0.8 and 0.5, in Belgium. The demographic projections
led in France to a reduction of AD prevalent patients of 25,295 (0.8) and 66,334 (0.5)
cases. This translated into annual savings in France of €559 million and €1.465
billion, respectively for RRR of 0.8 and 0.5. CONCLUSIONS: These analyses demon-
strate the large potential health-economic benefits of AD preventing interventions.
The results are robust across 9 major European countries and should encourage
intervention development and financing.
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